The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu
Principal Investigator
Carolina Solis-Herrera
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu
Arm | Description | Intervention |
---|---|---|
Placebo group | Subjects will be randomized to receive the empagliflozin placebo for 3 months | The placebo will be administered orally once per day for 3 months Other names:
|
Empagliflozin Group | Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months | Empagliflozin 25MG will be administered orally once per day for 3 months Other names:
|